About Us
Formed in 2016, the Enabling Technologies Consortium (ETC) is a forum for pharmaceutical and biotechnology companies to discuss ideas, share information, and collaborate on the development of new enabling technologies.
ETC gives member companies the ability to partner with external collaborators to further the mission of developing pre-competitive enabling technologies for pharmaceutical development and manufacturing. Pre-competitive projects are defined here as collaborations between multiple pharmaceutical companies and third parties designed to produce an efficiency-enhancing advancement or refinement that will ultimately be made broadly available to the public, either through publication, commercialization of a new product, or other means.
ETC streamlines these partnerships by eliminating the need for parallel agreements between each member company and the external party, providing a governance framework for the advancement of collaborative projects, and allowing for companies interested in enabling technologies to invest equally in their development.
ETC is also available to engage in feedback projects on newly developed commercial technologies upon request from instrument vendors.
Organization
ETC Board of Directors
The Board of Directors provides strategic oversight of the ETC® portfolio. The Board has representation from all member companies and is the primary decision-making body for ETC. Acting on the recommendations of working groups and on its own initiative, it establishes objectives, policies, and plans of action. Whenever possible, the Board operates on a consensus basis.
ETC Working Groups
Working Groups are standing, discipline-specific venues that allow experts in areas of pharmaceutical chemistry, manufacturing, and control to discuss key challenges and field proposals for new enabling technologies intended to address roadblocks for the industry. Learn more about our Working Groups.
ETC Project Teams
Project teams are groups of members interested in the development of specific techniques and tools to advance drug development and improve efficiency in the pharmaceutical and biotechnology industries. Project teams engage in collaborations with vendors and academics, research projects, and publications to further technology for the development and manufacture of pharmaceuticals.
ETC Members
- AbbVie
- Amgen
- AstraZeneca
- Biogen
- Boehringer Ingelheim
- Bristol Myers Squibb
- Eli Lilly
- Genentech/Roche
- Gilead
- GSK
- Johnson & Johnson
- Merck & Co.
- Novartis
- Pfizer
- Takeda
- Zoetis
How to Join
Eligibility
Companies that are significantly engaged in the development of new chemical entities or new molecular entities for the prevention, diagnosis, or treatment of disease are welcome to join ETC. For purposes of this provision, “significantly engaged” shall mean that a company is sponsoring at least one active Clinical Trial Application for a new chemical entity or new molecular entity.
Process
New Members must execute our Membership Agreement and pay the annual membership fee. The fee is prorated calculated from the month your company executes the Membership Agreement.
Membership Fee
Members of ETC pay an annual fee of $30,000 USD to cover the operating costs of the consortium. The Membership Fee is set annually by the ETC Board of Directors. In addition, members contribute a minimum of $20,000 USD annually towards their company’s Project Fee. The Project Fee is managed by the member’s Board of Directors representatives for the purpose of funding their share of projects executed by ETC. Any unspent funds at the end of the year carry forward to the next year.